DoMore Diagnositics is a newly established company in Oslo on a mission to transform cancer diagnostics with artificial intelligence. The technology is based on prominent international research from leading universities.
For five years, researchers at Oslo University Hospital, University of Oslo, University of Oxford and University College London have used deep learning and vast reserves of patient data to develop algorithms that provide the patients with a more precise prognosis to allow for better choices in treatment. The prognosis is calculated from a digitally transferred and stored scanned tumor sample – we call it “in silico pathology”. The excellent results have been published in international journals like Nature and Lancet.
The company is funded by Norselab and Grotmol Solutions.